The DOI matches its Crossref record.
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
Abstract
Aims: To evaluate the expression of the intermediate filament desmin in reactive mesothelium and malignant mesothelioma and to compare its utility with five other previously reported immunomarkers claimed to be of use in distinguishing reactive from neoplastic mesothelium. Methods and results: Sixty cases of malignant pleural mesothelioma and 40 cases of reactive mesothelial hyperplasia formed the study group. Cases were immunohistochemically stained with desmin, epithelial membrane antigen (EMA), p53, Bcl‐2, P‐glycoprotein and platelet‐derived growth factor receptor (PDGF‐R) β‐chain by the avidin–biotin complex method. The cohort of malignant pleural mesotheliomas were immunoreactive to desmin, EMA and p53 in 6/60 (10%), 48/60 (80%) and 27/60 (45%), respectively. In comparison, the cohort of reactive mesothelial hyperplasias were immunoreactive to desmin, EMA and p53 in 34/40 (85%), 8/40 (20%) and 0/40 (0%), respectively. In a smaller cohort (n = 15) of malignant pleural mesotheliomas, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were expressed in 0/15 (0%), 2/15 (13%) and 15/15 (100%), respectively. In a small cohort (n = 15) of reactive mesothelial hyperplasias, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were immunoreactive in 0/15 (0%), 0/15 (0%) and 6/15 (40%), respectively. Conclusions: Desmin and EMA appear to be the most useful markers in distinguishing benign from malignant mesothelial proliferations. Desmin appears to be preferentially expressed in reactive mesothelium and EMA appears to be preferentially expressed in neoplastic mesothelium. The complementary use of both markers is advocated in ascertaining the nature of mesothelial proliferations. Immunohistochemical detection of mutated p53 oncoprotein appeared to be of less utility in this study on account of the low marker sensitivity for malignant mesothelioma. However, p53 antibody may be of use as a second‐line marker of neoplastic mesothelium within a standard immunohistochemical panel of antibodies. In this study, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain appear to be of no use in distinguishing reactive from neoplastic mesothelium, although more formal evaluation of these markers is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Husain, A. N., Colby, T., Ordonez, N., Krausz, T., Attanoos, R., Beasley, M. B., Borczuk, A. C., Butnor, K., Cagle, P. T., Chirieac, L. R., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0214-oa · Cited by 473
Self-citationHusain, A. N., Colby, T. V., Ordóñez, N. G., Krausz, T., Borczuk, A., Cagle, P. T., Chirieac, L. R., Churg, A., Galateau-Salle, F., Gibbs, A. R., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.8.1317 · Cited by 332
Self-citationHida, T., Hamasaki, M., Matsumoto, S., Sato, A., Tsujimura, T., Kawahara, K., Iwasaki, A., Okamoto, T., Oda, Y., Honda, H., et al. (2016) · Pathology International · doi:10.1111/pin.12453 · Cited by 81
Metadata
- Authors
- Attanoos, R. L., Griffin, A., & Gibbs, A. R.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2003-08-27
- Volume
- 43
- Issue
- 3
- Pages
- 231-238
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2007303905
- Cited by
- 217
- References
- 0
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2. https://app.cochat.ai/papers/10.1046/j.1365-2559.2003.01686.x
- The paper
- Attanoos, R. L., Griffin, A., & Gibbs, A. R. (2003). The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2. Histopathology. https://doi.org/10.1046/j.1365-2559.2003.01686.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.